Tafolecimab Injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Innovent Biologics (Suzhou) Co., Ltd.
Medicine type: Biologic
Therapeutic area: Cardiovascular
Indications recorded in the public source: As an adjunct to diet, in combination with a statin, or with a statin and other lipid-lowering therapy, for adults with primary hypercholesterolemia (including heterozygous familial and nonfamilial hypercholesterolemia) or mixed dyslipidemia who have not achieved their LDL-C target despite moderate-dose or higher-dose statin treatment, to lower LDL-C, total cholesterol (TC) and apolipoprotein B (ApoB).
Indication source and scope: Source date(s): 2024, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
Prescribing-information limitations: Complete official prescribing information obtained. Mainland China label.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Limited to adults with primary hypercholesterolemia (including heterozygous familial and nonfamilial hypercholesterolemia) or mixed dyslipidemia who have not achieved their LDL-C target despite moderate-dose or higher-dose statin treatment.
Insurance period: 2025-01-01 to 2026-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions